Neovasc has announced that its Tiara technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012 (Paris, France, 15–18 May).
Shmuel Banai, medical director of Neovasc an associate professor of Medicine and Cardiology at the Tel Aviv University Sackler School of Medicine, will present data and several cases showing the successful implantation of the Tiara device in acute animal models.
Alexei Marko, CEO, Neovasc commented: “We are making excellent progress in the development of our Tiara technology for the transcatheter treatment of mitral valve disease, and we are pleased to have the opportunity to share our initial results in animals with leading interventional cardiologists at EuroPCR. With our strong background in vascular device and tissue heart valve development and manufacture, we believe we are well positioned to develop effective new therapies for this challenging condition. While the Tiara programme is early stage, development work to date has yielded promising results, and we hope to achieve the first implantations in humans in 2013.”
